{
    "xml": "<topic id=\"PHP5499\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/cisplatin\" basename=\"cisplatin\" title=\"CISPLATIN\">\n<title>CISPLATIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_877\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/platinum-compounds/cisplatin\">Cisplatin</xref>\n</p>\n<data name=\"vtmid\">57066004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_782175151\" title=\"Platinum compounds\">Platinum compounds</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP57381\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/cisplatin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer (alone or in combination)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57581\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/cisplatin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hydration</p>\n<p>Cisplatin requires intensive intravenous hydration and treatment may be complicated by severe nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57350\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/cisplatin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (platinum compounds).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57315\" outputclass=\"sideEffects\" rev=\"1.21\" parent=\"/drugs/cisplatin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">hypomagnesaemia</ph>; <ph outputclass=\"sideEffect\">myelosuppression</ph>; <ph outputclass=\"sideEffect\">nephrotoxicity</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">ototoxicity</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">severe nausea</ph>; <ph outputclass=\"sideEffect\">severe vomiting</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57549\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/cisplatin\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212; manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57348\" outputclass=\"pregnancy\" parent=\"/drugs/cisplatin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic and toxic in <i>animal</i> studies.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57598\" outputclass=\"breastFeeding\" parent=\"/drugs/cisplatin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57327\" outputclass=\"renalImpairment\" parent=\"/drugs/cisplatin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if possible&#8212;nephrotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57272\" outputclass=\"monitoringRequirements\" parent=\"/drugs/cisplatin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">Nephrotoxicity</p>\n<p>Monitoring of renal function is essential.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor full blood count.</p>\n<p>Monitor audiology.</p>\n<p>Monitor plasma electrolytes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57632\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/cisplatin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Cisplatin is increasingly given in a day care setting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57214\" outputclass=\"nationalFunding\" rev=\"1.34\" parent=\"/drugs/cisplatin\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA55</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Paclitaxel for ovarian cancer (January 2003)</p>\r\n<p>\r\n<i>Either</i> paclitaxel in combination with a platinum compound (cisplatin or carboplatin) <i>or</i> a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA55\">www.nice.org.uk/TA55</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA91</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p>\r\n<p>Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA91\">www.nice.org.uk/TA91</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised that docetaxel (<i>Taxotere</i>\n<tm tmtype=\"reg\"/>) in combination with cisplatin and fluorouracil is accepted for restricted use within NHS Scotland for the induction treatment of patients with unresectable (May 2007) and resectable (June 2008) locally advanced squamous cell carcinoma of the head and neck.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5499-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/cisplatin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75728\" title=\"Solution for infusion\" namespace=\"/drugs/cisplatin/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"1\" rel=\"backlink\">Cytotoxic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_877\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/platinum-compounds/cisplatin\" title=\"Cisplatin\" count=\"1\" rel=\"link\">Cisplatin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75728\" namespace=\"/drugs/cisplatin/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5499",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/cisplatin",
    "basename": "cisplatin",
    "title": "CISPLATIN",
    "interactants": [
        {
            "id": "bnf_int_877",
            "label": "Cisplatin"
        }
    ],
    "vtmid": "57066004",
    "drugClassification": [
        "Platinum compounds"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer (alone or in combination)",
                        "html": "Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer (alone or in combination)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature).",
                        "html": "<p>(consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Hydration",
                "textContent": "Cisplatin requires intensive intravenous hydration and treatment may be complicated by severe nausea and vomiting.",
                "html": "<p>Cisplatin requires intensive intravenous hydration and treatment may be complicated by severe nausea and vomiting.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (platinum compounds).",
                "html": "<p>Appendix 1 (platinum compounds).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypomagnesaemia",
                        "html": "hypomagnesaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression",
                        "html": "myelosuppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nephrotoxicity",
                        "html": "nephrotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ototoxicity",
                        "html": "ototoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe nausea",
                        "html": "severe nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe vomiting",
                        "html": "severe vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins&#8212; manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins&#8212; manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic and toxic in animal studies.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic and toxic in <i>animal</i> studies.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if possible&#8212;nephrotoxic.",
                "html": "<p>Avoid if possible&#8212;nephrotoxic.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "Nephrotoxicity",
                "textContent": "Monitoring of renal function is essential.",
                "html": "<p>Monitoring of renal function is essential.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor full blood count.\n\nMonitor audiology.\n\nMonitor plasma electrolytes.",
                "html": "<p>Monitor full blood count.</p><p>Monitor audiology.</p><p>Monitor plasma electrolytes.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Cisplatin is increasingly given in a day care setting.",
                "html": "<p>Cisplatin is increasingly given in a day care setting.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA55",
                        "label": "www.nice.org.uk/TA55"
                    }
                ],
                "fundingIdentifier": "NICE TA55",
                "textContent": "Paclitaxel for ovarian cancer (January 2003) Either paclitaxel in combination with a platinum compound (cisplatin or carboplatin) or a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).\n\nwww.nice.org.uk/TA55",
                "html": "<p outputclass=\"title\">Paclitaxel for ovarian cancer (January 2003)</p> <p> <i>Either</i> paclitaxel in combination with a platinum compound (cisplatin or carboplatin) <i>or</i> a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA55\">www.nice.org.uk/TA55</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA91",
                        "label": "www.nice.org.uk/TA91"
                    }
                ],
                "fundingIdentifier": "NICE TA91",
                "textContent": "Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy.\n\nwww.nice.org.uk/TA91",
                "html": "<p outputclass=\"title\">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p> <p>Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA91\">www.nice.org.uk/TA91</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75728",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_877",
                "label": "Cisplatin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75728",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}